ArticleStem cells international2026
miR-329-3p in Bone Marrow Mesenchymal Stem Cells-Derived Exosomes Promotes Bone Regeneration in Diabetic Fractures by Alleviating the SIRT3-Mediated Oxidative Stress via Inhibiting LSD1.
Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extracellular Vesicles and Their Role in Osteogenesis.Bioengineering (Basel, Switzerland) · 2026Review
- miR-329-3p in Bone Marrow Mesenchymal Stem Cells-Derived Exosomes Promotes Bone Regeneration in Diabetic Fractures by Alleviating the SIRT3-Mediated Oxidative Stress via Inhibiting LSD1.Stem cells international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Influence of bone marrow mesenchymal stem cells (BMSCs)-derived exosomes (Exo) on fracture healing in diabetes mellitus (DM) was investigated. Methods: Serum LSD1, SIRT3, superoxide dismutase (SOD), and malondialdehyde (MDA) were detected in patients with diabetic fractures. Under high-glucose (HG) conditions, influences of LSD1, SIRT3, BMSCs-derived Exo, and BMSCs-derived Exo harboring miR-329-3p on osteogenic differentiation and oxidative stress of MC3T3-E1 cells were assayed via ALP staining, western blotting, dichlorofluorescin diacetate (DCFH-DA) staining, and enzyme-linked immunosorbent assay (ELISA). Mice with diabetic fractures were treated by BMSCs, BMSCs-derived Exo, or a combination of BMSCs and GW4869. Western blotting and immunohistochemistry examined protein expression in fracture tissues. Results: DM patients with nonunion showed higher serum LSD1 and MDA and lower serum SIRT3 and SOD than those with normal fracture healing. In HG-induced MC3T3-E1 cells, LSD1 silencing upregulated SIRT3, RUNX2, OPG, and SOD, increased mature osteoblasts, and reduced reactive oxygen species (ROS) and MDA; SIRT3 silencing revered these results. LSD1 downregulated SIRT3, RUNX2, OPG, and SOD, reduced mature osteoblasts, and enhanced ROS and MDA in HG-induced MC3T3-E1 cells; BMSCs-derived Exo abrogated these influences. BMSCs-derived Exo harboring miR-329-3p suppressed LSD1 and ROS, upregulated SIRT3, RUNX2, and OPG, and increased mature osteoblasts in HG-induced MC3T3-E1 cells. BMSCs transplantation in diabetic fracture mice elevated SIRT3, ALP, RUNX2, OPG, and miR-329-3p and reduced LSD1 in fracture tissues; miR-329-3p silencing in BMSCs or GW4869 treatment of mice counteracted these effects. Conclusion: BMSCs-derived Exo harboring miR-329-3p induces bone regeneration in diabetic fractures by relieving the SIRT3-mediated oxidative stress via inhibiting LSD1. It has potential in treating diabetic fractures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.